Latest Production Development News

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.

RAS Technology Holdings (ASX:RTH) posted a 34% revenue increase to $28.4 million for FY2026, driven by expansion across all business units and geographic markets including Asia and the UK. Despite this, significant investments in product development and trading capabilities led to a normalized net loss after tax of $0.3 million.

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

WiseTech Global posted a record $1.4 billion in revenue for FY26, driven by the e2open acquisition and AI-led efficiencies, while underlying net profit rose 29%. The company outlines a confident FY27 growth outlook amid ongoing integration and innovation.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

Netwealth Group posted record FY26 revenue of $391 million, up 21%, with adjusted net profit rising 16.2% to $135.4 million after excluding $105 million in First Guardian compensation. The company declared a fully franked 21-cent final dividend, maintaining a 9.1% increase in total dividends.

Atturra Limited’s FY26 results reveal a sharp net loss driven by a $22.8 million goodwill impairment, overshadowing a 17% revenue increase to $351.8 million. The company is banking on AI and strategic acquisitions to fuel a turnaround in FY27.

Monvia Limited reported a $28.7 million revenue year with a $6.9 million adjusted EBITDA, exceeding IPO forecasts, while renewing a $60 million contract with MetLife and completing its ASX listing.